Timothy Tipoe

Guy's And St Thomas Hospital NHS Foundation Trust, St George's University Hospital
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; The RIO Trial.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy.

Journal: medRxiv : the preprint server for health sciences

Published: February 12, 2026

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Time to HIV rebound after infusion of long-acting broadly neutralising antibodies 3BNC117-LS and 10-1074-LS and analytical treatment interruption (the RIO trial): a double-blind, randomised, placebo-controlled trial.

Journal: The lancet. HIV

Published: December 09, 2025

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies.

Journal: Nature communications

Published: October 29, 2024

Impact of antiretroviral therapy during primary HIV infection on T-cell immunity after treatment interruption.

Impact of antiretroviral therapy during primary HIV infection on T-cell immunity after treatment interruption.

Journal: European journal of immunology

Published: April 16, 2024

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: May 18, 2022

An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.

An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.

Journal: Current opinion in HIV and AIDS

Published: April 19, 2022

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

Journal: JCI insight

Published: December 08, 2021

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Journal: Nature communications

Published: June 15, 2021

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Journal: The lancet. HIV

Published: April 19, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026